AU2001277725A1 - Cytokine production inhibitors - Google Patents

Cytokine production inhibitors

Info

Publication number
AU2001277725A1
AU2001277725A1 AU2001277725A AU7772501A AU2001277725A1 AU 2001277725 A1 AU2001277725 A1 AU 2001277725A1 AU 2001277725 A AU2001277725 A AU 2001277725A AU 7772501 A AU7772501 A AU 7772501A AU 2001277725 A1 AU2001277725 A1 AU 2001277725A1
Authority
AU
Australia
Prior art keywords
cytokine production
production inhibitors
inhibitors
hydrate
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001277725A
Inventor
Hiroaki Naka
Hideki Tokushige
Shuichi Yokogaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Kyorin Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd, Kyorin Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Publication of AU2001277725A1 publication Critical patent/AU2001277725A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A cytokine production inhibitor which comprises as an active component gatifloxacin, a hydrate thereof or a salt thereof.
AU2001277725A 2000-08-14 2001-08-09 Cytokine production inhibitors Abandoned AU2001277725A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-245831 2000-08-14
JP2000245831 2000-08-14
PCT/JP2001/006839 WO2002013830A1 (en) 2000-08-14 2001-08-09 Cytokine production inhibitors

Publications (1)

Publication Number Publication Date
AU2001277725A1 true AU2001277725A1 (en) 2002-02-25

Family

ID=18736277

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001277725A Abandoned AU2001277725A1 (en) 2000-08-14 2001-08-09 Cytokine production inhibitors

Country Status (10)

Country Link
US (1) US20030176444A1 (en)
EP (1) EP1312364B1 (en)
KR (1) KR100771025B1 (en)
AT (1) ATE345801T1 (en)
AU (1) AU2001277725A1 (en)
CA (1) CA2419178C (en)
DE (1) DE60124732T2 (en)
ES (1) ES2273872T3 (en)
TW (1) TWI287987B (en)
WO (1) WO2002013830A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0300521A (en) * 2003-03-13 2005-03-22 Halex Star Ind Farmaceutica Lt Process for obtaining stable isotonic injectable solution of predefined glucose diluted gatifloxacin, stable injectable solution of predifined glucose diluted gatifloxacin, closed-loop packaging process of the obtained injectable solution, use of closed system for packaging solution of injectable gatifloxacin, use of the prediluted glucose-diluted gatifloxacin solution for injection and method of administration
GB2400033A (en) * 2003-03-29 2004-10-06 Secr Defence Use of fluoroquinolone antibiotics for the treatment of Q fever
CN1307995C (en) * 2005-10-12 2007-04-04 周卓和 Gatifloxacin eye drop and its preparing method
EP2026822A4 (en) * 2006-06-12 2012-07-04 Therakine Ltd Topical treatment for diseases of eye surface

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH089597B2 (en) * 1986-01-21 1996-01-31 杏林製薬株式会社 8-Alkoxyquinolonecarboxylic acid excellent in selective toxicity and its salt, and method for producing the same
WO1990001950A1 (en) * 1988-08-19 1990-03-08 Celltech Limited Pharmaceutical products for anti-neoplastic therapy
WO1994020105A1 (en) * 1993-03-10 1994-09-15 Otsuka Pharmaceutical Company, Limited Interleukin-1 inhibitor
JP3449658B2 (en) * 1994-12-21 2003-09-22 杏林製薬株式会社 8-Alkoxyquinolonecarboxylic acid hydrate excellent in stability and method for producing the same
US6010711A (en) * 1996-01-26 2000-01-04 University Of Rochester Methods, articles and compositions for the pharmacologic inhibition of bone resorption with phosphodiesterase inhibitors
JPH10130149A (en) * 1996-07-12 1998-05-19 Sankyo Co Ltd Tnf production inhibitor
JPH10130240A (en) * 1996-10-30 1998-05-19 Dai Ichi Seiyaku Co Ltd Inhibitor of icam-1-production
SE9803710L (en) * 1998-09-25 2000-03-26 A & Science Invest Ab Use of certain substances for the treatment of nerve root damage

Also Published As

Publication number Publication date
TWI287987B (en) 2007-10-11
KR20030024866A (en) 2003-03-26
DE60124732T2 (en) 2007-10-04
DE60124732D1 (en) 2007-01-04
WO2002013830A1 (en) 2002-02-21
KR100771025B1 (en) 2007-10-29
EP1312364B1 (en) 2006-11-22
ATE345801T1 (en) 2006-12-15
EP1312364A1 (en) 2003-05-21
US20030176444A1 (en) 2003-09-18
ES2273872T3 (en) 2007-05-16
EP1312364A4 (en) 2004-05-12
CA2419178A1 (en) 2003-02-13
CA2419178C (en) 2009-05-12

Similar Documents

Publication Publication Date Title
EP1549315A4 (en) Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
WO2002074748A8 (en) Metalloproteinase inhibitors
AU2002250394A1 (en) Rho-kinase inhibitors
AU2002245709A1 (en) Rho-kinase inhibitors
WO2004018457A8 (en) Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors
AU2003249442A1 (en) Kinase inhibitors
WO2004018451A8 (en) Pyridazinone-derivatives as pde4 inhibitors
AU2003222055A1 (en) Kinase inhibitors
WO2004018449A8 (en) Piperidine-derivatives as pde4 inhibitors
AU2003248872A1 (en) Hiv integrase inhibitors
HK1054034A1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors.
MXPA03009847A (en) Pyrazole derived kinase inhibitors.
MXPA03007310A (en) Phthalayinone-piperidino-derivatives as pde4 inhibitors.
AU2003237446A1 (en) Pyrazole-derivatives as p38 kinase inhibitors
AP2003002856A0 (en) Broadspectrum 2-(substitutted-amino)-benzothiazolesulphonamide HIV protease inhibitors.
AU2003212310A1 (en) (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
AP2005003451A0 (en) HIV integrase inhibitors.
WO2005028474A3 (en) Pyrazoloquinoline derivatives as chk-1 inhibitors
AP2006003484A0 (en) Nicotinamide derivatives useful as PDE4 inhibitors.
WO2001078654A3 (en) Halogentated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
AU2001277725A1 (en) Cytokine production inhibitors
AP2005003231A0 (en) Beta-lactamase inhibitor prodrug.
AUPS251402A0 (en) Kinase inhibitors
AU2003293886A1 (en) (1,7)naphthyridines as pde4 inhibitors
AU2002253633A1 (en) 20-hydroxyeicosatetraenoic acid production inhibitors